CTOs on the Move

VaxGen

www.b2i.us

 
VaxGen Inc. is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.b2i.us
  • 379 Oyster Point Blvd Ste 10
    South San Francisco, CA USA 94080
  • Phone: 650.624.2439

Executives

Name Title Contact Details

Similar Companies

Loyale

Loyale is reinventing the way healthcare providers engage with their patients financially. With Loyale`s end-to-end suite of solutions, providers of all types and configurations are elevating their patients` financial experiences to a level that compares with their clinical experiences. With Loyale, providers build durable, trusting relationships with patients. They also increase revenues, reduce staff time & stress, and minimize bad debt.

Modern Vascular Management

Modern Vascular is a group of healthcare companies headquartered in Phoenix, AZ. Modern Vascular clinics specialize in the treatment of peripheral artery disease (PAD) through infrapopliteal, inframalleolar, and pedal endovascular arterial reconstruction. Most patients report reduced pain, rapid wound healing, and a better quality of life post procedure. Modern Vascular procedures are also an important step in avoiding future limb amputation and extending life expectancy in diabetic, cardiovascular, and peripheral artery disease patients. Modern Vascular now operates and manages thirteen clinics across AZ, CO, MS, NM, TX, VA

Avivia Health From Kaiser Permanente

Avivia Health From Kaiser Permanente is a Oakland, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Americana Dental Inc

Americana Dental Inc is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Telesta Therapeutics

Telesta Therapeutics is a biopharmaceutical company focused on the development, manufacturing and commercialization of transformative human therapeutics. Our main focus is on novel medicines that address major unmet medical needs, particularly in oncology. Our anchor product, MCNA, has completed a Phase III pivotal study in patients with non-muscle invasive bladder cancer that have failed the first line therapy, bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application (BLA) for MCNA with the U.S. FDA on June 29, 2015 and is seeking, upon marketing approval in the U.S., to make MCNA available for patients and their physicians. Our ultimate goal is to transform the treatment landscape and prolong and improve the lives of those affected by bladder cancer, one of the most common types of cancers today.